The U.S. FDA has approved Bristol Myers Squibb (BMS)’ Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor. According to BMS, Sotyktu is the first TYK2 inhibitor to be approved for PsA. PsA Defined and How Sotyktu Helps PsA can best be defined as a chronic, immune-mediated, heterogeneous disease that can have multiple musculoskeletal or skin manifestations. Among these symptoms may be infla...